Nutra Pharma is expected to use the grant proceeds to support additional clinical work on its pain treatments.
Nutra Pharma chairman and CEO Rik Deitsch said that it was an honor to receive the grant and to be recognised by the US Federal Government for their work developing new analgesics.
"We intend to use the proceeds from this grant to support our ongoing clinical development program for our pain relievers, which include Cobroxin and Nyloxin," Deitsch said.
The QTDP Program was enacted in 2010 by the US Congress as part of the Patient Protection and Affordable Care Act.